Hematology and Blood Disorders

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (202) 780-3397

Opinion Article - Hematology and Blood Disorders (2024) Volume 7, Issue 4

Understanding Thrombophilia: Genetic and Acquired Risk Factors

Esther Fox *

Department of Medicine, University of Colorado School of Medicine, USA

*Corresponding Author:
Esther Fox
Department of Medicine, University of Colorado School of Medicine, USA
E-mail: esther.fox@cuanschutz.edu

Received: 2-Jan-2024, Manuscript No. aahbd-25-159339; Editor assigned: 4-Jan-2024, PreQC No. aahbd-25-159339 (PQ) Reviewed:17-Jan-2024, QC No. aahbd-25-159339Revised:24-Jan-2024, Manuscript No. aahbd-25-159339; Published:31-Jan-2024, DOI: 10.35841/aahbd-7.4.204

Citation: Fox E. Understanding thrombophilia: Genetic and acquired risk factors. Hematol Blood Disord. 2024;7(4):204

Visit for more related articles at Hematology and Blood Disorders

Introduction

Thrombophilia refers to a group of disorders that predispose individuals to develop abnormal blood clotting, which can lead to dangerous conditions such as deep vein thrombosis (DVT), pulmonary embolism (PE), and stroke. These conditions are a result of an imbalance in the blood’s coagulation system, where the tendency to form blood clots becomes exaggerated. Thrombophilia can either be genetic or acquired, with both types contributing to the risk of clot formation. Understanding the underlying risk factors—genetic mutations, environmental factors, and lifestyle choices—can help in the early detection and management of thrombophilia, ultimately preventing serious complications [1].

Genetic thrombophilia occurs when an individual inherits certain mutations that increase the likelihood of developing blood clots. One of the most well-known genetic causes of thrombophilia is the Factor V Leiden mutation. This mutation results in an altered version of Factor V, a protein essential in the coagulation cascade. The mutation makes Factor V resistant to inactivation by activated protein C, leading to a hypercoagulable state. People with one copy of the mutated gene (heterozygous) have a 3 to 8 times higher risk of developing clots, while those with two copies (homozygous) have a significantly higher risk [2].

Another genetic mutation that contributes to thrombophilia is prothrombin G20210A mutation. This mutation leads to elevated levels of prothrombin, a clotting factor, in the blood. Increased prothrombin levels enhance clot formation, which raises the risk of thrombosis. Like Factor V Leiden, prothrombin mutation can be inherited in a dominant pattern, meaning that individuals who inherit one copy of the mutated gene from a parent are at a greater risk of developing thrombotic events [3].

Antithrombin III (ATIII) is a protein that naturally inhibits clotting factors, including thrombin and Factor Xa, thereby preventing excessive clot formation. A deficiency in ATIII, whether congenital or acquired, increases the risk of venous thromboembolism (VTE). Congenital ATIII deficiency is inherited in an autosomal dominant manner, and individuals with this condition have a higher likelihood of developing DVT or PE. In addition to the genetic form, acquired ATIII deficiency may occur due to conditions such as liver disease or nephrotic syndrome, further elevating thrombotic risk [4].

Protein C and protein S are natural anticoagulants that help regulate the coagulation system by inactivating clotting factors Va and VIIIa. Deficiencies in either of these proteins can lead to a hypercoagulable state and increase the risk of thrombosis. Both protein C and protein S deficiencies can be inherited, and individuals with these conditions are prone to recurrent clotting events, particularly deep vein thrombosis and pulmonary embolism. These deficiencies are often diagnosed through blood tests that measure the activity of protein C and S [5].

While genetic factors play a significant role in thrombophilia, acquired conditions can also increase the risk of developing abnormal clotting. One of the most common acquired risk factors is pregnancy. During pregnancy, particularly in the third trimester, women experience changes in their coagulation system, such as increased levels of clotting factors and decreased levels of natural anticoagulants. Additionally, pregnancy-related conditions like preeclampsia or gestational diabetes can further increase the risk of thrombosis [6].

The use of oral contraceptives or hormone replacement therapy (HRT) is another major acquired risk factor for thrombophilia. Estrogen-containing contraceptives and HRT can increase the levels of certain clotting factors, thereby elevating the risk of thrombotic events. Women who carry genetic mutations like Factor V Leiden or prothrombin mutation may have an even higher risk when taking these hormonal therapies, which is why healthcare providers often screen for thrombophilia before prescribing such treatments [7].

Obesity is a well-established risk factor for thrombosis due to its impact on inflammatory markers, coagulation factors, and blood flow. Excess weight contributes to a hypercoagulable state, and obesity is often associated with other conditions that increase clotting risk, such as hypertension and diabetes. Additionally, physical inactivity or prolonged immobility, such as during long flights or post-surgery recovery, can lead to sluggish blood flow and increased risk of clot formation. Combining obesity with sedentary behavior significantly raises the risk of developing venous thromboembolism [8].

Certain cancers also predispose individuals to thrombosis due to the secretion of procoagulant substances by tumors. This is particularly true for cancers of the pancreas, lung, and ovaries. Additionally, antiphospholipid syndrome (APS), characterized by the presence of antiphospholipid antibodies in the blood, is another acquired condition that increases clotting risk. These antibodies, such as anticardiolipin antibodies and lupus anticoagulant, interfere with normal clotting mechanisms and are strongly associated with venous and arterial thrombosis [9].

Chronic inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, and systemic lupus erythematosus (SLE) can also contribute to thrombophilia. The inflammation increases the production of clotting factors and reduces the effectiveness of natural anticoagulants, leading to a prothrombotic state. Similarly, surgical procedures can increase the risk of clot formation due to tissue injury, immobility, and the release of clot-promoting substances [10].

Conclusion

Thrombophilia, whether genetic or acquired, plays a significant role in the development of thrombotic events that can have life-threatening consequences. By understanding both the genetic mutations and acquired conditions that contribute to thrombophilia, healthcare providers can offer targeted management strategies to reduce the risk of clot formation. Early detection, lifestyle changes, and appropriate medical interventions are essential to managing thrombophilia and preventing the complications associated with abnormal blood clotting.

References

  1. Matschke J, Müller-Beissenhirtz H, Novotny J, et al. A Randomized Trial of daily prednisone versus pulsed dexamethasone in treatment-naïve adult patients with immune thrombocytopenia: EIS 2002 Study.. Acta Haematol. 2018;98(3):1132-9.

    2. Indexed at, Google Scholar, Cross Ref

  2. Wei Y, Ji XB, Wang YW, et al. High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial .Blood. 2016;127(3):296-302.

    3. Indexed at, Google Scholar, Cross Ref

  3. Nakazaki K, Hosoi M, Hangaishi A, et al. Comparison between pulsed high-dose dexamethasone and daily corticosteroid therapy for adult primary immune thrombocytopenia: a retrospective study.Intern Med. 2012;51(8):859-63.

    4. Indexed at, Google Scholar, Cross Ref

  4. Sakamoto K, Nakasone H, Tsurumi S, et al. Prednisone versus high-dose dexamethasone for untreated primary immune thrombocytopenia. A retrospective study of the Japan Hematology & Oncology Clinical Study Group .J Thromb Thrombolysis. 2014;37(3):279-86.

    5. Indexed at, Google Scholar, Cross Ref

  5. Albelda SM. Role of integrins and other cell adhesion molecules in tumor progression and metastasis..Lab Invest. 2001;12(8):499-506.

    6. Indexed at, Google Scholar

  6. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C.. Proc Natl Acad Sci. 1993;90(3):1004-8.

    7. Indexed at, Google Scholar, Cross Ref

  7. McCully K. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Clin Pathol. 1969;56(1):111.

    8. Indexed at, Google Scholar

  8. Sabatino M, Ren J, David-Ocampo V, et al. The establishment of a bank of stored clinical bone marrow stromal cell products. J Transl Med. 2012;10(1):1-2.

    9. Indexed at, Google Scholar, Cross Ref

  9. Park TS, Rosenberg SA, Morgan RA. Treating cancer with genetically engineered T cells. Trends Biotechnol. 2011;29(11):550-7.

    10. Indexed at, Google Scholar, Cross Ref

  10. Restifo NP, Dudley ME, Rosenberg SA. . Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol. 2012;12(4):269-81.

    11. Indexed at, Google Scholar, Cross Ref

Get the App